An update on treatment options for pancreatic adenocarcinoma
Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …
late diagnosis, and limited treatment options, it is expected to be the second leading cause …
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
I Garrido-Laguna, M Hidalgo - Nature reviews Clinical oncology, 2015 - nature.com
Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020.
The survival rates for patients with other gastrointestinal malignancies have increased …
The survival rates for patients with other gastrointestinal malignancies have increased …
Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective …
Objective: This study was performed to determine whether neoadjuvant treatment increases
survival in patients with BRPC. Summary Background Data: Despite many promising …
survival in patients with BRPC. Summary Background Data: Despite many promising …
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Ducreux, AS Cuhna, C Caramella… - Annals of …, 2015 - annalsofoncology.org
A recent study estimating cancer epidemiology in 2014 (within Europe) showed that
pancreatic cancer was the fourth most fatal cancer in men after lung, colorectal, and prostate …
pancreatic cancer was the fourth most fatal cancer in men after lung, colorectal, and prostate …
Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma
Objectives: To establish an evidence-based cut-off to differentiate between early and late
recurrence and to compare clinicopathologic risk factors between the two groups. Summary …
recurrence and to compare clinicopathologic risk factors between the two groups. Summary …
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial
Background Pancreatic ductal adenocarcinoma are known to metastasise early and a
rationale exists for the investigation of preoperative chemotherapy in patients with …
rationale exists for the investigation of preoperative chemotherapy in patients with …
Current and future therapies for advanced pancreatic cancer
R Gupta, I Amanam, V Chung - Journal of surgical oncology, 2017 - Wiley Online Library
Pancreatic cancer remains a deadly disease with a 5‐year survival rate of only 8%. Even
after surgical resection, most patients have recurrence of their cancer. Over the last 10 years …
after surgical resection, most patients have recurrence of their cancer. Over the last 10 years …
[HTML][HTML] Current standards and new innovative approaches for treatment of pancreatic cancer
T Conroy, JB Bachet, A Ayav, F Huguet… - European Journal of …, 2016 - Elsevier
Pancreatic adenocarcinoma remains a devastating disease with a 5-year survival rate not
exceeding 6%. Treatment of this disease remains a major challenge. This article reviews the …
exceeding 6%. Treatment of this disease remains a major challenge. This article reviews the …
Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which …
Objective The objective of the study is to evaluate the usefulness of neoadjuvant
chemoradiotherapy in resectable pancreatic cancer. Methods A single-center RCT of …
chemoradiotherapy in resectable pancreatic cancer. Methods A single-center RCT of …
Chemotherapy and radiotherapy for advanced pancreatic cancer
Background Pancreatic cancer (PC) is a highly lethal disease with few effective treatment
options. Over the past few decades, many anti‐cancer therapies have been tested in the …
options. Over the past few decades, many anti‐cancer therapies have been tested in the …